India-based Gennova Biopharmaceuticals Ltd. confirmed it had been granted authorization to conduct phase 2/3 clinical trials for the mRNA-based COVID-19 vaccine candidate HGCO19.

Gennova submitted the proposed Phase II and Phase III study entitled “A Prospective, Multicentre, Randomized, Active-controlled, Observer-blind, Phase II study seamlessly followed by a Phase III study to evaluate safety and tolerability, and immunogenicity of the vaccine candidate HGCO19 in healthy subjects."
https://www.precisionvaccinations.com/2021/08/26/indias-mrna-covid-...